EATG » Side effects

Side effects

Efavirenz in pregnancy is at least as safe as other antiretrovirals

No safety signal for raltegravir either An individual patient data analysis of almost 25,000 pregnancies in women living with HIV has found that the rate of birth defects following exposure…

Sleep abnormalities do not reverse after discontinuing efavirenz

For patients with HIV receiving efavirenz-based therapy, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of treatment, according to results published in HIV Clinical Trials. These results also suggest…

Do integrase inhibitors raise the risk of obesity?

People who take an integrase inhibitor as part of their HIV treatment appear to gain more weight than others after starting treatment and the trend is more common in women…

Efavirenz likely safe for pregnant HIV-positive women

The prevalence of birth defects following use of efavirenz (EVF)-based antiretroviral therapy (ART) is not statistically different from non-EFV-based ART during conception or in the first trimester, researchers say. Most…

Doubt cast on link between tenofovir disoproxil and bone fractures

Study raises questions about the value of switching to more expensive tenofovir alafenamide Treatment with tenofovir disoproxil fumarate (TDF) does not increase the risk of fractures, according to French research…

HIV i-Base, HTB: HIVR4P and Glasgow conferences: first reports

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. This issue of HTB includes the first reports from the recent HIV Treatment for Prevention (HIVR4P) and Glasgow…

Jury still out on neural tube defects from dolutegravir

GLASGOW — Ever since four infants with neural tube defects were born to women in Botswana who were using dolutegravir at conception, researchers and surveillance experts have been scrambling to…

HIV Glasgow 2018: NAM, NATAP reports

2018 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2018), 28-31 October 2018, Glasgow, UK   NAM reports: Hepatitis C increases the risk of premature delivery for pregnant…

Cardiovascular risk unclear for HIV patients on dolutegravir

GLASGOW — Patients with HIV who switched to a dolutegravir-based regimen from a ritonavir-boosted protease inhibitor regimen experienced body mass gain and changes in biomarkers related to increased insulin resistance,…

HIV Glasgow 2018: NAM reports (part 1)

2018 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2018), 28-31 October 2018, Glasgow, UK Neural tube defects and integrase inhibitors: studies show no further evidence of increased…

1 2 3 13